ICU Medical's Earnings Call Highlights Replacement Cycle Delays, VitalCare Stabilization Doubts, and Revised Japanese Exit Impact

Date of Call: Aug 6, 2026

Financials Results

• Revenue: $548 million, 6% organic growth, 1% reported growth
• EPS: $2.37 adjusted diluted earnings per share, up 13% YOY
• Gross Margin: 41% adjusted gross margin, in line with expectations

Guidance:

• Full-year adjusted EBITDA guidance raised and narrowed to $415-$435 million.
• Full-year adjusted EPS guidance raised and narrowed to $8.60-$9.00 per share.
• Full-year adjusted gross margin expected to be higher at around 41.5%.
• Adjusted operating expenses expected to be approximately 25% of revenue.
• Net interest expense expected to be approximately $65 million.
• Full-year earnings contribution from the JV expected to be breakeven or a small loss.

Business Commentary:

Revenue Growth and Business Performance:

• ICU Medical reported revenue of $548 million for Q2 2026, representing a 6% organic growth and 1% reported growth.
• The growth was primarily driven by North America, with stable demand and utilization environment, as well as contributions from the infusion systems and consumables businesses.

Infusion Systems and Consumables Strength:

• The IV systems business grew 13% reported and 12% organic, with record sales in pumps, while the consumables business achieved a 6% reported growth and 5% organic growth.
• Growth in these segments was attributed to competitive wins, strong demand for new products, and balanced growth across product families.

Financial Metrics and Margins:

• Adjusted gross margin for Q2 was 41%, with adjusted EBITDA improving to $110 million, and adjusted EPS was $2.37.
• Margin improvement was driven by operational efficiencies, favorable tariff expense adjustments, and synergy capture from integration projects.

Debt Reduction and Leverage Target:

• ICU Medical repaid $50 million of debt in Q2, reducing the net leverage ratio to 2.3 times.
• The debt repayment was facilitated by strong organic free cash flow and tariff refunds, aligning with the company's target of approximately two times leverage by year-end.

Tariff and Currency Impacts:

• The company experienced higher logistics expenses due to elevated diesel costs, offset by lower tariff expenses as Section 122 tariffs had lower average rates compared to original guidance.
• Currency fluctuations, particularly in the Costa Rican Cologne, Mexican peso, and Japanese yen, had a negative impact on financial results over the past four years.

Sentiment Analysis:

Overall Tone: Positive

• "We're pleased with the business performance through the first half of this year, including record revenues for both infusion systems and consumables, and the continued gross margin expansion." "Although recent volatility... we believe the momentum we have in the business positions us to exceed the goals we've established at the beginning of the year."

Q&A:

• Question from Jason Bedford (Raymond James): Is the 12% system strength reflective of an uptick in the replacement cycle?
  Response: Strength was from early installations and competitive wins; the upgrade cycle hasn't started earnestly.

• Question from Jason Bedford (Raymond James): On LVP pricing dynamics with Duo and Solo, is price sticking?
  Response: Price is in line with value; management believes the device's value merits the current pricing.

• Question from Jason Bedford (Raymond James): Is the $10 million crude impact still part of the guidance framework?
  Response: The impact is now incorporated into guidance based on latest oil/diesel prices.

• Question from Jason Bednar (Piper Sandler): Can you size the earlier than expected installations in infusion systems?
  Response: Management is confident in maintaining organic growth at or above 6% for the near term.

• Question from Jason Bednar (Piper Sandler): What are the real-time competitive dynamics and order inflows for infusion systems?
  Response: Dynamics are normal with no uber acceleration; management feels good about the current book.

• Question from Jason Bednar (Piper Sandler): Any update on MedFusion 5000 submission timing?
  Response: Amended package will go back to FDA sometime this year; prioritizing completion to serve large upgrade base.

• Question from Brett Fishman (Keyvent Capital Markets): How much more is there to squeeze from skew rationalization?
  Response: Most work is done; VitalCare line is stabilizing with easier comps.

• Question from Brett Fishman (Keyvent Capital Markets): Any update on CAD timing?
  Response: CAD timing will follow MedFusion 5000 submission; no specific timing given.

• Question from Larry Salo (TJS Securities): What was the OEM headwind for systems growth?
  Response: OEM was a meaningful drag but is now largely wound down; it was a timing issue.

• Question from Larry Salo (TJS Securities): Have you had any customer feedback on replacement cycles?
  Response: Customer upgrade timing varies; management respects their capital cycles and doesn't pressure upgrades.

• Question from Larry Salo (TJS Securities): What's the outlook for free cash flow and remediation expenses?
  Response: On track for ~$150 million free cash flow goal; restructuring/remediation spend will decrease in H2.

• Question from Larry Salo (TJS Securities): Is the longer-term 200 bps gross margin target mostly from completed actions?
  Response: Target requires continued price and product mix efforts; not all from completed actions.

• Question from Mike Mattson (Needham & Company): Could there be additional tariff refunds?
  Response: Potential for some further refunds, but not approaching the $20 million received.

• Question from Mike Mattson (Needham & Company): Is the impact from oil prices worse than anticipated?
  Response: Impact is largely in line with Q1 expectations, though volatile; guidance incorporates current outlook.

• Question from Mike Mattson (Needham & Company): Will IT systems efficiency improvements continue?
  Response: Benefits are not temporary, but Q2 run rate is not the right future run rate.

• Question from Sam Iber (BTIG): What's driving consumables growth?
  Response: Growth driven by solid census, admissions, and North America performance, with less price than last year.

• Question from Sam Iber (BTIG): Any catalyst for a VitalCare deal?
  Response: No rush; waiting for the right intersection of fit, value, and ease; logical alternatives are being pursued.

Contradiction Point 1

Infusion Systems Replacement Cycle Timing

Contradiction on when the broader upgrade cycle will gain momentum, impacting the company's growth outlook.

Larry Salo (TJS Securities) - Larry Salo (TJS Securities)

2026Q2: The broader replacement cycle is expected to gain more momentum beginning in 2027. - Vivek Jain(CEO)

What was the approximate headwind from the OEM wind-down on the ambulatory side in Q2, and what is the current status of the replacement cycle? - Jason Bedford (Raymond James)

2026Q2: The upgrade cycle has not truly begun. - Vivek Jain(CEO)

Contradiction Point 2

Sustainability of IT Systems Efficiency Gains on SG&A

Contradiction on whether the SG&A reduction from IT benefits is temporary or a new baseline, affecting financial forecasting.

Mike Mattson (Needham & Company) - Mike Mattson (Needham & Company)

2026Q2: The IT efficiency benefits are not temporary but the Q2 run rate is not the right baseline for future SG&A... - Brian Bunnell(CFO)

Was the impact of oil price increases worse than anticipated, and will the IT-driven SG&A reductions be sustainable? - Mike Matson (Needham & Company)

2026Q2: The Q2 run rate is the target; the company would invest more if given the chance. - Vivek Jain(CEO)

Contradiction Point 3

Assessment of the VitalCare Business

Stance shifts from expecting business to stabilize to still being significantly impacted, affecting strategic and financial expectations.

Brett Fishman (Keyvent Capital Markets) - via Alon - Brett Fishman (Keyvent Capital Markets) - via Alon

2026Q2: The work in VitalCare (primarily product line exits) is largely done... The business was significantly impacted in Q1 but is now expected to stabilize, with easier year-over-year comparisons going forward. - Vivek Jain(CEO)

What is the remaining potential from prior product skew rationalization efforts and their contribution? - Jayson Bedford (Raymond James)

2026Q1: We haven’t exit. We’ve announced the exit. We’ve made a very small transaction to do that, but it’s still on the income statement today. A little bit of the 10 is related to that product line continuing to shrink. It’s literally nickels and dimes in the other areas. - Vivek Jain(CEO)

Contradiction Point 4

Impact of the Japanese Product Line Exit

Magnitude of ongoing headwind downgraded from ~$10M annual to a minor "point or two drag," affecting financial modeling.

Larry Salo (TJS Securities) - Larry Salo (TJS Securities)

2026Q2: The OEM headwind was 'meaningful' but is expected to be a 'point or two drag' on the segment for the remainder of the year. - Vivek Jain(CEO)

What was the impact of the OEM wind-down on the ambulatory side in Q2, and what is the current status of the replacement cycle? - Jason Bednar (Piper Sandler)

2026Q1: I think you’re overthinking that, sir... It’s, it’s drifted down $10 million. - Vivek Jain(CEO)

Contradiction Point 5

Outlook on the Infusion Systems Replacement Cycle

Timing for significant replacement cycle momentum shifts from 2027 to no clear near-term acceleration, impacting growth expectations.

Larry Salo (TJS Securities) - Larry Salo (TJS Securities)

2026Q2: The broader replacement cycle is expected to gain more momentum beginning in 2027. - Vivek Jain(CEO)

What was the approximate headwind from the OEM wind-down on the ambulatory side in Q2, and can you update us on the replacement cycle? - Michael Toomey (Jefferies)

2026Q1: Yes... we’re starting those conversations today... The real energy, I think, again, will be towards the end of this year. The timing sort of lines up more with next year, the competitive opportunities are what we should spend our time on if they’re here. - Vivek Jain(CEO)